N/A
Completed N=13
Reward-Based Recovery Outcomes Management for Opioid Use Disorder
Source: ClinicalTrials.gov NCT04669249 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcomePrimary: Percentage of Participants Fully-Adherent to Buprenorphine — 6; 3 Participants
Summary
A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in treatment care, and adherence to medication for opioid use disorder.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Fully-Adherent to Buprenorphine |
6; 3 | — |
| PRIMARY Percentage of Participants Fully-Adherent to Care Plan |
4; 2; 6; 3 | — |
| PRIMARY Percentage of Participants Completing Outcomes Monitoring Surveys |
7; 4 | — |
| SECONDARY Percentage of Participants Using Opioids |
1; 1 | — |
| SECONDARY Percentage of Participants Using Other Substances (Non-opioids) |
2; 2 | — |
| SECONDARY Change in Quality of Life as Assessed by EUROHIS-QOL 8-item Index From Baseline to 4-Week Follow-up |
4.57; 1.50 | — |
| SECONDARY Change in Opioid Craving as Assessed by Opioid Craving Scale (OCS) From Baseline to 4-Week Follow-up |
19.42; 16.50 | — |
| SECONDARY Motivation as Assessed by Readiness Ruler |
93.49; 89.31 | — |
| SECONDARY Change in Self-Efficacy as Assessed by Brief Situational Confidence Questionnaire (BSCQ) From Baseline to 4-Week Follow-up |
54.62; 38.44 | — |
| SECONDARY Change in Opioid Use Disorder Impairment From Baseline to 4-Week Follow-up |
9.86; 7.50 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- access to internet-enabled smartphone device
- primary DSM-5 opioid use disorder diagnosis
- receiving medication treatment for opioid use disorder with buprenorphine
- English language proficient
Exclusion Criteria
- active suicidal ideation or psychotic symptoms
Data sourced from ClinicalTrials.gov (NCT04669249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.